Biogen Inc logo

Biogen Inc

50
6
NAS:BIIB (USA)  
$ 217.81 -0.25 (-0.11%) 10:08 PM EST
27.19
P/B:
2.07
Market Cap:
$ 31.71B
Enterprise V:
$ 37.58B
Volume:
761.78K
Avg Vol (2M):
1.19M
Also Trade In:
Volume:
761.78K
Avg Vol (2M):
1.19M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for BIIB ( Biogen Inc ) from 1991 to May 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Biogen stock (BIIB) PE ratio as of May 27 2024 is 27.19. More Details

Biogen Inc (BIIB) PE Ratio (TTM) Chart

To

Biogen Inc (BIIB) PE Ratio (TTM) Historical Data

Total 1237
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Biogen PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-27 27.2 2024-03-22 27.3
2024-05-24 27.2 2024-03-21 27.7
2024-05-23 27.2 2024-03-20 27.3
2024-05-22 28.1 2024-03-19 27.4
2024-05-21 28.4 2024-03-18 27.5
2024-05-20 28.9 2024-03-15 27.5
2024-05-17 28.8 2024-03-14 27.5
2024-05-16 28.7 2024-03-13 28.4
2024-05-15 29.4 2024-03-12 28.5
2024-05-14 28.3 2024-03-11 28.8
2024-05-13 28.1 2024-03-08 28.0
2024-05-10 27.6 2024-03-07 27.5
2024-05-09 27.8 2024-03-06 27.3
2024-05-08 27.4 2024-03-05 27.2
2024-05-07 27.3 2024-03-04 27.7
2024-05-06 27.6 2024-03-01 27.7
2024-05-03 27.1 2024-02-29 27.2
2024-05-02 26.7 2024-02-28 27.8
2024-05-01 27.0 2024-02-27 28.1
2024-04-30 26.8 2024-02-26 28.0
2024-04-29 26.9 2024-02-23 28.0
2024-04-26 26.1 2024-02-22 27.9
2024-04-25 25.3 2024-02-21 27.7
2024-04-24 25.2 2024-02-20 27.5
2024-04-23 24.1 2024-02-16 27.4
2024-04-22 24.2 2024-02-15 28.0
2024-04-19 24.3 2024-02-14 27.7
2024-04-18 23.8 2024-02-13 28.4
2024-04-17 24.0 2024-02-12 30.7
2024-04-16 24.4 2024-02-09 30.2
2024-04-15 24.6 2024-02-08 30.1
2024-04-12 24.7 2024-02-07 30.1
2024-04-11 25.4 2024-02-06 30.8
2024-04-10 25.2 2024-02-05 30.3
2024-04-09 25.8 2024-02-02 30.5
2024-04-08 25.6 2024-02-01 31.1
2024-04-05 25.4 2024-01-31 30.9
2024-04-04 25.6 2024-01-30 31.0
2024-04-03 25.8 2024-01-29 31.0
2024-04-02 25.9 2024-01-26 30.7
2024-04-01 26.8 2024-01-25 30.9
2024-03-28 26.9 2024-01-24 31.0
2024-03-27 27.1 2024-01-23 31.5
2024-03-26 26.6 2024-01-22 31.1
2024-03-25 27.1 2024-01-19 31.3

Biogen Inc (BIIB) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.